TiumBio

TiumBio, based in Seongnam, South Korea, is a biotechnology company. TiumBio develops treatments for rare and intractable diseases, including immunotherapies and biologics for cancer, hemophilia and endometriosis. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing TU2218 in biliary tract cancer, head and neck squamous cell carcinoma and colorectal cancer. The largest, NCT05204862 (Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumours), plans to enrol 240 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.